FIG. 2.

Difference between PL9643 and placebo at weeks 2 and 12 for the population with moderate to severe DED for corneal and conjunctival fluorescein staining (A) and corneal and conjunctival Lissamine Green staining (B). Note: Treatment difference was LS (SE) change from pre-CAE baseline to post-CAE for each treatment LS mean change from baseline. Fluorescein and Lissamine Green staining were measured with the Ora Calibra Corneal and Conjunctival Staining Scale. *Nominal P < 0.05 versus placebo through analysis of covariance. Note: the type I error for secondary endpoints was not adjusted for multiplicity. Therefore, statistical significance for these endpoints should be viewed as hypothesis generating and not as statistical evidence. CAE, controlled adverse environment; DED, dry eye disease; LS, least squares; SE, standard error.